Tanya Gurevich
A5024978718- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Lysosomal Storage Disorders Research
- Genetic Neurodegenerative Diseases
- Balance, Gait, and Falls Prevention
- Botulinum Toxin and Related Neurological Disorders
- Cerebral Palsy and Movement Disorders
- Neurological diseases and metabolism
- Cellular transport and secretion
- Restless Legs Syndrome Research
- RNA regulation and disease
- Ginkgo biloba and Cashew Applications
- Autism Spectrum Disorder Research
- Nuclear Receptors and Signaling
- Voice and Speech Disorders
- Dysphagia Assessment and Management
- Alzheimer's disease research and treatments
- Advanced Neuroimaging Techniques and Applications
- Cannabis and Cannabinoid Research
- Parkinson's Disease and Spinal Disorders
- Functional Brain Connectivity Studies
- Cardiovascular Syncope and Autonomic Disorders
- Amyotrophic Lateral Sclerosis Research
- Attention Deficit Hyperactivity Disorder
- Genetics and Neurodevelopmental Disorders
Tel Aviv Sourasky Medical Center
2016-2025
Tel Aviv University
2016-2025
Arthur M. Sackler Gallery
2017-2021
Northwestern University
2020
Radboud University Nijmegen
2014-2018
Radboud University Medical Center
2014-2018
Parkinson's Foundation
2018
University of North Carolina at Chapel Hill
2018
University Medical Center
2018
HealthPartners
2018
Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain GBA ethnically diverse group disease.Sixteen centers participated our international, collaborative study: five from Americas, six Europe, two Israel, and three Asia. Each center genotyped standard DNA panel permit comparison genotyping results across centers. Genotypes phenotypic...
To assess the effect of levodopa on distinct freezing gait (FOG) subtypes in patients with ‘off’ FOG. Nineteen (12 men, mean age 62.0 ± 8.4 years) Parkinson's disease and clinically significant FOG during states were videotaped whilst walking 130 m ‘on’ states. Three independent observers characterized type, duration, clinical manifestations quantified by analyzing videotapes. Their combined scores used for statistical analysis. The intra‐class correlation coefficient assessed inter‐observer...
BackgroundMultiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that characterised by autonomic failure, cerebellar ataxia, parkinsonism in various combinations. Here we present the final analysis of prospective multicentre study European MSA Study Group to investigate natural history MSA.MethodsPatients with clinical diagnosis were recruited followed up clinically for 2 years. Vital status was ascertained years after completion. Disease...
<b>Background: </b> Mutations in <i>GBA</i> and <i>LRRK2</i> genes have been implicated Parkinson disease (PD), particularly Ashkenazi Jews. <b>Methods: An Israeli cohort of 420 patients with PD, 333 elderly controls, 3,805 young controls was screened for eight mutations, which are associated mild (N370S, R496H) severe (84GG, IVS2 + 1, V394L, D409H, L444P, RecTL) Gaucher disease. Patients PD were also genotyped G2019S. <b>Results: </b><i>GBA</i> carrier frequency 17.9% compared to 4.2% 6.35%...
Objectives To study the association of subjective memory complaints (SMC) with affective state and cognitive performance in elders. Materials methods We studied community dwelling elderly persons normal physical examination. Participants completed questionnaires regarding difficulties lifestyle habits, Geriatric Depression Scale (GDS) Spielberger State-Trait Anxiety Inventory (STAI). Depending on their answers to question about condition, participants were divided into complainers...
Estimates of the spectrum and frequency pathogenic variants in Parkinson's disease (PD) different populations are currently limited biased. Furthermore, although therapeutic modification several genetic targets has reached clinical trial stage, a major obstacle conducting these trials is that PD patients largely unaware their status and, therefore, cannot be recruited. Expanding number investigated PD-related genes including related to disorders with overlapping features large,...
Multiple system atrophy (MSA) is a Parkinson's Disease (PD)-like α-synucleinopathy clinically characterized by dysautonomia, parkinsonism, cerebellar ataxia, and pyramidal signs in any combination. We aimed to determine whether the clinical presentation of MSA as well diagnostic therapeutic strategies differ across Europe Israel. In 19 European Study Group centres all consecutive patients with diagnosis were recruited from 2001 2005. A standardized minimal data set was obtained patients....
The clinical diagnosis of multiple system atrophy (MSA) is fraught with difficulty and there are no pathognomonic features to discriminate the parkinsonian variant (MSA-P) from Parkinson's disease (PD). Besides poor response levodopa, additional presence pyramidal or cerebellar signs (ataxia) autonomic failure as major diagnostic criteria, certain other known "red flags" warning may raise suspicion MSA. To study role these in MSA-P versus PD patients, a standardized red flag check list...
To study the possible association of founder mutations in lysosomal storage disorder genes HEXA, SMPD1, and MCOLN1 (causing Tay-Sachs, Niemann-Pick A, mucolipidosis type IV diseases, respectively) with Parkinson disease (PD).Two PD patient cohorts Ashkenazi Jewish (AJ) ancestry, that included a total 938 patients, were studied: cohort 654 patients from Tel Aviv, replication 284 New York. Eight AJ analyzed. The frequencies these compared to control groups large published undergoing prenatal...
ABSTRACT Background Reduced arm swing is a well‐known clinical feature of Parkinson's disease (PD), often observed early in the course disease. We hypothesized that subtle changes and axial rotation may also be detectable prodromal phase. Objective The purpose this study was to evaluate relationship between LRRK2‐ G2019S mutation, swing, healthy nonmanifesting carriers noncarriers mutation patients with PD. Methods A total 380 participants (186 controls 194 PD patients) from 6 sites...
Estimates of the penetrance LRRK2 G2019S vary widely (24%-100%), reflective differences in ascertainment, age, sex, ethnic group, and genetic environmental modifiers.The kin-cohort method was used to predict 2,270 relatives 474 Ashkenazi Jewish (AJ) Parkinson disease (PD) probands Michael J. Fox AJ Consortium New York Tel Aviv, Israel. Patients with PD were genotyped for mutation at least 7 founder GBA mutations. carriers excluded. A validated family history interview, including age onset...
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are most common genetic determinant of Parkinson disease (PD) identified to date, and have been implicated both familial sporadic forms disease. The G2019S change LRRK2 exon 41 has associated with at varying frequencies Asian, European, North American, African populations, is particularly prevalent among Ashkenazi Jews.We assessed occurrence G2019S, I2012T, I2020T, R1441G/C/H mutations our cohort Jewish Israeli patients PD,...
Abstract To test for an association between the LRRK2 ‐G2019S mutation and gait, we studied 52 first‐degree relatives of patients with Parkinson's disease (PD) who carry this mutation. An accelerometer quantified gait during usual‐walking, fast‐walking, dual‐tasking. Noncarriers (n = 27) carriers 25) were similar respect to age, gender, height, speed all conditions. During dual‐tasking variability amplitude dominant peak signal significantly altered among carriers. These findings support...
ABSTRACT The phenotype of Parkinson's disease (PD) in patients with and without leucine‐rich repeat kinase 2 ( LRRK2 ) G2019S mutations reportedly is similar; however, large, uniformly evaluated series are lacking. objective this study was to characterize the clinical Ashkenazi Jewish (AJ) PD carriers mutation. We studied 553 AJ patients, including 65 who were previously reported, from three sites (two New York one Tel‐Aviv). Glucocerebrosidase GBA mutation excluded. Evaluations included...
ABSTRACT Background : Higher levels of serum cholesterol are well‐established risk factors for coronary artery disease and stroke. The role in neurodegeneration is not clear. Objective We evaluated the association between over time Parkinson's (PD) among statin‐free individuals. Methods A population‐based cohort study 261,638 individuals (aged 40‐79 years at their first test, 42.7% men), with repeated measures total, low, high‐density lipoprotein was performed from 1999 to 2012. Individuals...